Drug Profile
Trastuzumab biosimilar - AbbVie/Amgen/Byondis
Alternative Names: ABP-980; Herceptin biosimilar - Allergan/Amgen/Byondis; Kanjinti; Trastuzumab beta - Allergan/Amgen/Byondis; Trastuzumab-annsLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Synthon
- Developer AbbVie; Amgen; Daiichi Sankyo Company
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Gastric cancer
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 16 Apr 2020 Synthon Biopharmaceuticals is now called Byondis
- 01 Oct 2019 West German Study Group, Amgen, Merck Sharp & Dohme Corp. and NanoString Technologies plans a phase II trial in Breast cancer (Early stage disease, Neoadjuvant therapy, Combination therapy) with molecular HER2-enriched intrinsic subtype (IV) (NCT03988036)